Monthly F&O expiry triggered consolidation as positive global AI sentiment and FII inflows collided with US tariff/Iran negotiation uncertainty, causing intraday gains to evaporate.
Healthcare, pharma, and PSU banks outperformed amid defensive rotation, while auto and oil & gas rallied early; consumer discretionary lagged as risk appetite waned.
Midcap and smallcap indices gained 4.72% and 5.10% over one month respectively, signaling domestic capital rotation from large-cap tech toward unloved cyclicals and value plays.
FIIs net bought ₹2,991 crore Wednesday while DIIs purchased ₹5,119 crore, establishing domestic buying floor; however, February's $2.44bn FII inflows represent pause, not reversal, per analysts.
Intraday volatility spiked midweek due to expiry mechanics; benchmarks oscillated between 25,325-25,700 support/resistance as participants hedged positioning ahead of fiscal year-end.
Key Indices
NIFTY 50
25,497
0.06%
SENSEX
82,248.61
-0.03%
Momentum Snapshot
Index
Price
1D
1M
1Y
Sensex
82,248.61
-0.03%
0.48%
10.23%
Nifty Midcap 100
59,798
0.66%
4.64%
20.31%
Nifty Next 50
70,629
0.33%
6.59%
19.08%
Nifty Smallcap 250
16,047
0.07%
4.79%
11.12%
Nifty 50
25,497
0.06%
1.79%
13.08%
Market Sentiment
MMI Score
55.25
Greed
MMI is in the greed zone. It suggests that investors are acting greedy in the market, but the action to be taken depends on the MMI trajectory.
Since last week: Sentiment moved from Greed (52.59) to Greed (55.25).
Sector Highlights
Pharma
+1.08%
No summary available
PSU Bank
+0.95%
No summary available
Auto
+0.80%
No summary available
FMCG
-0.16%
No summary available
Media
-0.68%
No summary available
Sector Scoreboard
Sector
1D
1W
1Y
3Y
Pharma
+1.08%
+2.26%
+13.84%
+92.16%
PSU Bank
+0.95%
+1.68%
+66.43%
+170.55%
Auto
+0.80%
+0.49%
+31.41%
+121.20%
FMCG
-0.16%
-0.57%
-0.66%
+14.84%
Media
-0.68%
-3.14%
-4.88%
-18.13%
Stock Spotlight Of The Day
Sanofi Consumer Healthcare
Market Cap
Cr
Current Price
₹
Stock P/E
Dividend Yield
%
ROCE
%
ROE
%
Shareholding Changes (Impact Factors)
FIIs
QoQ
-0.11%
YoY
-1.59%
Stable foreign holding
DIIs
QoQ
0.12%
YoY
-8.02%
Stable domestic holding
Promoters
QoQ
0%
YoY
10.87%
No change in promoter holding
Quarterly Summary (Absolute)
Sales
Expenses
Operating Profit
Net Profit
Profit & Loss (Compounded)
Sales Growth
10 Years
None%
5 Years
None%
3 Years
None%
TTM
None%
Profit Growth
10 Years
None%
5 Years
None%
3 Years
None%
TTM
None%
Stock Price CAGR
10 Years
None%
5 Years
None%
3 Years
None%
1 Year
None%
Return on Equity
10 Years
None%
5 Years
None%
3 Years
None%
Last Year
None%
Fundamentals Corner
The company's fundamentals are strengthening on the bottom line through superior margin expansion and a resilient ROE, even as top-line sales growth shows signs of reaching a mature plateau.
However, growth momentum is visibly slowing when comparing 10-year CAGRs to recent 3-year performance, and the current premium valuation appears stretched given that the latest quarterly results show rising expenses and cooling operating profits.
News TidBits
The stock surged 16% following an impressive Q4 performance that saw net profit jump 50% year-on-year to ₹66.5 crore.
Management announced a substantial dividend of ₹75 per share, demonstrating strong cash flow generation and a commitment to shareholder returns.
Robust consumer demand for branded healthcare products and a post-pandemic focus on wellness are the primary drivers for this profit surge.
As an MNC pharma play, it serves as a defensive hedge for investors looking to avoid sectors heavily exposed to volatile US tariff policies.
The company's performance reinforces the current 'buy-on-dips' consensus for the pharma sector, which is seeing widespread earnings upgrades.
Stacks on Stacks: Tip Time 🤑
Always distinguish between a fundamental collapse and a technical adjustment; Angel One’s 90% price drop was a liquidity-enhancing stock split, not a loss of value, reminding investors to read corporate actions before reacting to charts.
Metals Market
Commodity
Price
Day
Monthly
YoY
Gold
USD/t.oz
5174.96
0.2%
-0.12%
79.96%
Silver
USD/t.oz
87.575
-1.83%
-21.9%
180.51%
Copper
USD/Lbs
5.9797
-0.1%
2.02%
31.38%
Steel
CNY/T
3063
-0.23%
-1.54%
-6.47%
Lithium
CNY/T
173000
6.96%
0.29%
129.6%
Iron Ore CNY
CNY/T
748.5
-0.53%
-4.35%
-7.25%
Platinum
USD/t.oz
2284.2
-2.04%
-9.98%
140.59%
HRC Steel
USD/T
987.08
0.11%
2.29%
9.07%
Iron Ore
USD/T
99.07
-0.08%
-6.67%
-7.54%
Silicon
CNY/T
8250
-1.32%
-5.93%
-20.94%
Scrap Steel
USD/T
372.5
-0.4%
-0.4%
4.2%
Titanium
CNY/KG
45.5
0%
0%
-1.09%
Precious metals have entered a sharp rally driven by geopolitical safe-haven demand, with Gold prices climbing 0.2% daily and Silver extending a massive six-day winning streak despite some intraday volatility.
Industrial metals like Copper and Steel are benefiting from a recovery in global demand and the Indian government's continued emphasis on infrastructure spending, which is acting as a structural catalyst for metal consumption.
The Lithium market saw a significant daily jump of nearly 7%, reflecting a renewed focus on EV battery supply chains even as other industrial commodities like Iron Ore face slight downward pressure.
Analysts suggest the sector is entering a 'strong bull phase' or supercycle, recommending a buy-on-dips strategy for retail investors to gain exposure to manufacturing cycles and energy transition themes.
Top News Developments
Defense Sector Rally Fueled by Ammunition Deals and Global Pact Rumors
Balu Forge signed a five-year MoU for large calibre ammunition, providing long-term revenue visibility and positioning the firm for high-margin exports.
Speculation regarding a new India-Israel defense pact for missile technology transfer is driving fresh interest in state-run majors like HAL and BEL.
The sector is benefiting from a structural shift in global supply chains as international buyers move away from Russia-Ukraine sourcing toward Indian manufacturing.
Sustained infrastructure order wins for firms like RVNL, with a ₹60,000+ crore backlog, ensure the defense and rail segments remain primary engines for mid-cap value creation.
Pharma Turnaround Triggered by GLP-1 Entry and Import Substitution
Indian firms like Zydus and Biocon are aggressively positioning for the global anti-obesity market (semaglutide), forecasting a massive growth cycle starting in 2026.
Aurobindo Pharma's move into large-scale penicillin manufacturing marks a strategic effort to break China's dominance in basic drug ingredients under government PLI schemes.
The sector is seeing a wave of earnings upgrades as US price erosion eases and favorable currency movements boost export margins for leaders like Sanofi and Mankind Pharma.
Agricultural exporters like LT Foods are also seeing sentiment boosts following significant reductions in US trade duties.
Banking Resilience and Airtel's Fintech Pivot Disrupt Credit Markets
Public Sector Banks are showing superior loan-to-deposit ratios and credit resilience, while private lenders face higher regulatory scrutiny on capital exposure.
Bharti Airtel's ₹20,000 crore investment into its new NBFC signals a transition to direct lending, leveraging its massive subscriber base to challenge traditional banks.
The consolidation of the payments space continues, highlighted by BillDesk's acquisition of Worldline India's operations to strengthen its omnichannel merchant presence.
Banking stocks have anchored recent market gains as the RBI maintains a policy stance that encourages credit growth while keeping rates steady.
IT Sector Volatility as AI Disruption Fears Meet Valuation Resets
The Nifty IT index suffered a 21% downturn in February due to fears that new AI tools from Anthropic could disrupt traditional services models.
Forward-looking players like LTIMindtree and XTGlobal are carving out niches in AI infrastructure and public sector contracts to hedge against terminal decline risks.
Analysts view the current sell-off as a 'tech cycle' opportunity to buy specialized firms that are successfully integrating NVIDIA-backed AI analytics.
Despite short-term volatility, the transition of Indian IT from low-cost labor to high-value engineering via Global Capability Centers (GCCs) remains a key long-term theme.
FII / DII Snapshot
Yesterday
FII Net: ₹2991.64 cr
DII Net: ₹5118.57 cr
January 2026
FII Net: ₹-41435.22 cr
DII Net: ₹69220.74 cr
Daily Flows
Date
FII Net
DII Net
25-Feb-2026
₹2991.64 cr
₹5118.57 cr
24-Feb-2026
₹-102.53 cr
₹3161.22 cr
23-Feb-2026
₹3483.70 cr
₹-1292.24 cr
20-Feb-2026
₹-934.61 cr
₹2637.15 cr
19-Feb-2026
₹-880.49 cr
₹-596.28 cr
Monthly Flows
Month
FII Net
DII Net
January 2026
₹-41435.22 cr
₹69220.74 cr
December 2025
₹-34349.62 cr
₹79619.91 cr
November 2025
₹-17500.31 cr
₹77083.78 cr
October 2025
₹-2346.89 cr
₹52794.02 cr
September 2025
₹-35301.36 cr
₹65343.59 cr
August 2025
₹-46902.92 cr
₹94828.55 cr
IPO Watchlist
Ongoing IPOs
Omnitech Engineering (₹583 Cr size) is currently open with a modest 1.54% Grey Market Premium and 0.14x subscription, reflecting cautious investor interest.
PNGS Reva Diamond Jewel is trading at a slight discount of -0.26% in the grey market, while SME segment subscriptions continue to see extreme retail exuberance ranging from 100x to 350x.
Omnitech Engineering
583.00
Date: 25 Feb - 27 Feb
List: 5 Mar
Subscription: 0.14x
GMP: 1.54%
PNGS Reva Diamond Jewellery T
380.00
Date: 24 Feb - 26 Feb
List: 4 Mar
Subscription: 1.3x
GMP: -0.26%
Upcoming IPOs
Sedemac Mechatronics is scheduled to open on March 4, with its nearly ₹6,000 crore valuation highlighting strong appetite for deeptech firms with global manufacturing footprints.
The National Stock Exchange (NSE) has officially invited investment banks to pitch for its own long-delayed IPO following SEBI clearance, which is expected to be one of India's most significant market listings by mid-2026.
SEDEMAC Mechatronics
1087.45
Date:4 Mar - 6 Mar
List:11 Mar
Subscription: -
GMP: 0.00%
Cha-Ching Cheatsheet 💵
In a market characterized by extreme SME IPO exuberance and 'story stocks,' the most durable alpha is often found by rotating into undervalued sectors with confirmed earnings quality rather than chasing 300x subscription hype.
Global Markets
Country
Index
1D
1Y
3Y
🇰🇷 South Korea
KOSPI
3.54%
138.81%
162.51%
🇹🇭 Thailand
SET Composite
1.15%
24.57%
-5.76%
🇺🇸 USA
S&P 500
0.81%
16.62%
74.96%
🇫🇷 France
CAC
0.78%
7.14%
18.24%
🇩🇪 Germany
DAX
0.43%
10.92%
66.23%
🇯🇵 Japan
Nikkei 225
0.25%
53.59%
114.15%
🇬🇧 UK
FTSE
0.12%
24.81%
36.35%
🇨🇳 China
Shanghai Composite
-0.01%
23.93%
27.27%
🇮🇳 India
GIFT NIFTY
-0.07%
13.38%
46.57%
🇸🇬 Singapore
Straits Times
-0.87%
26.78%
52.13%
🇮🇩 Indonesia
Jakarta Composite
-1.06%
25.02%
20.14%
🇭🇰 Hong Kong
Hang Seng
-1.48%
14.51%
32.25%
Wall Street's AI-driven rally to two-week highs eased disruption cost concerns, reducing risk-off pressure on emerging markets and enabling FII reentry into Indian equities.
Weaker dollar boosted gold prices and aided rupee stability, improving carry returns on rupee assets versus alternatives; currency tailwind supported valuation multiples.
US tariff policy uncertainty and Iran negotiations created macro overhang, forcing participants to hedge exposure despite positive technical setups—growth expectations suspended pending clarity.
Asian equities' fourth consecutive session of gains reflected AI volatility decompression; however, cautious Nvidia reaction signaled traders differentiating winners/losers rather than broad risk-on.
Modest crude oil stability contained inflation expectations, enabling defensive sectors (pharma, healthcare) to attract capital without rate-hike fears—energy hedge demand remained muted.
Emerging Opportunities
Auto ancillaries and forged components breaking out; Balu Forge surged 10% on ammunition supply MOU—geopolitical demand cycle early, valuations compressed from 2025 underperformance.
Midcap pharma/healthcare outperforming large-cap tech 4.72% over month; Sanofi Consumer jumped 16% on profit growth and dividends—domestic demand secular, tariff-insulated, margin-expanding.
PSU banks index gaining while private banks consolidate; rate-cut cycle emerging in February FII flows—valuation gap widest versus Nifty in three years, institutional rotation imminent.
IT sector selective strength despite $1.21bn February selling; valuations moderated, continued outflows 'less compelling'—contrarian entry for quality names on 5-10% dip into 25,325 support.
Export-led auto OEMs (Tata Motors +2.93%) rising on tariff certainty premium; supply chain regionalization favors India-based manufacturers against China—structural tailwind unpriced into consensus estimates.
Policy & Regulations
The RBI has intensified its regulatory pressure on Kotak Mahindra Bank, maintaining a ban on onboarding new customers due to persistent compliance and technology concerns, which continues to weigh on the bank's market sentiment.
SEBI's introduction of Life Cycle Funds is set to transform the mutual fund industry by shifting the focus toward goal-based, automated asset allocation for long-term retail investors.
New regulatory amendments aimed at curbing bank lending for speculative purposes may increase costs for domestic proprietary traders, potentially shifting the competitive advantage toward global high-frequency trading firms.
The exclusion of GST from mutual fund distributor payouts starting April 2026 will force a major restructuring of brokerage rates, impacting the profitability of smaller distribution networks.
A recent NCLAT ruling allowing a class action suit against Jindal Poly Films over fund siphoning allegations marks a critical milestone for minority shareholder protection frameworks in India.
Crypto Buzz
Name
Price
Market Cap
24h Change
ATH Change
Bitcoin (BTC)
$68235
$1.36T
4.40%
-45.88%
Ethereum (ETH)
$2059.95
$248.58B
7.28%
-58.35%
Tether (USDT)
$1
$183.63B
0.02%
-24.42%
XRP (XRP)
$1.44
$87.82B
4.45%
-60.54%
BNB (BNB)
$623.56
$85.02B
3.19%
-54.48%
Bitcoin has rebounded toward the $68,000 mark, supported by massive spot ETF inflows of over $500 million which have successfully absorbed recent selling pressure.
Ethereum outperformed the broader market with an 8.5% surge, leading to significant short-position liquidations and improving overall risk appetite for digital assets.
Despite the recovery, legal risks remain a persistent overhang for the industry, particularly following new insider trading suits against major global crypto players.
Institutional adoption is evolving with new products like tokenized money-market funds, though retail investors are cautioned to remain mindful of the high volatility observed in recent cycles.
